Strategy& – Re-inventing Pharma with Artificial Intelligence

The future of pharma and healthcare is expected to be personalized and digital, with AI playing a crucial role in accelerating this convergence. Pharmaceutical companies can incorporate AI into new products and services, or use it to make processes more productive and efficient. The focus of this report is on the indirect value of AI and its various use cases. Recent research shows that pharma companies can potentially double their operating profit by 2030 by industrializing AI across their organizations. AI use cases in operations, R&D, commercial, and enabling functions all contribute to this increased efficiency. By 2030, pharma companies could gain an additional $254bn in annual operating profits worldwide from AI, with the US and Europe leading in potential profits. AI is expected to have a significant impact on research beyond 2030, further increasing the divide between AI leaders and followers in terms of revenues and value chain efficiencies.